WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526249

CAS#: 531-76-0

Description: Sarcolysin is an antineoplastic agent used an anti-cancer chemotherapy drug.

Chemical Structure

CAS# 531-76-0

Theoretical Analysis

MedKoo Cat#: 526249
Name: Sarcolysin
CAS#: 531-76-0
Chemical Formula: C13H18Cl2N2O2
Exact Mass: 304.0745
Molecular Weight: 305.2
Elemental Analysis: C, 51.16; H, 5.94; Cl, 23.23; N, 9.18; O, 10.48

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Sarcolysin; DL-Sarcolysin; DL-Sarcolysine; Merfalan; Merphalan; NCI-CO4944; NSC-14210.

IUPAC/Chemical Name: 4-(Bis(2-chloroethyl)amino)-DL-phenylalanine


InChi Code: InChI=1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 305.2 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Boldyrev IA, Grechishnikova IV, Pavlova IuB, Molotkovskiĭ IuG. [Synthesis and properties of fluorescently-labelled triglyceride, derivative of the antineoplastic agent sarcolysin]. Bioorg Khim. 2004 Jan-Feb;30(1):80-3. Russian. PubMed PMID: 15040307.

2: Gullbo J, Wallinder C, Tullberg M, Lövborg H, Ehrsson H, Lewensohn R, Nygren P, Luthman K, Larsson R. Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2. Mol Cancer Ther. 2003 Dec;2(12):1331-9. PubMed PMID: 14707274.

3: Mironiuk TA, Korsakov MV, Reztsova VV, Kon'kov SA, Zhdanova EA, Krasnov VP, Filov VA. [Chemobiokinetics of sarcolysin and its peptides with glutaminic acid]. Vopr Onkol. 2000;46(5):583-7. Russian. PubMed PMID: 11202192.

4: Roboz J, Jiang J, Holland JF, Bekesi JG. Selective tumor apoptosis by MF13, L-prolyl-L-m-[bis(chloroethyl)amino]-phenylalanyl-L-norvaline ethyl ester, a new sarcolysin containing tripeptide. Cancer Res. 1997 Nov 1;57(21):4795-802. PubMed PMID: 9354441.

5: Kozlov AM, Korchagina EIu, Vodovozova EL, Bovin NV, Molotkovskiĭ IuL, Syrkin AB. [Enhancement of antineoplastic activity of sarcolysin by the means of transforming it into lipid derivative and incorporating into liposomal membranes containing carbohydrate vector]. Biull Eksp Biol Med. 1997 Apr;123(4):439-41. Russian. PubMed PMID: 9190189.

6: Vodovozova EL, Nikol'skiĭ PIu, Mikhalev II, Molotkovskiĭ IuG. [Lipid derivatives of sarcolysin, methotrexate and rubomycin]. Bioorg Khim. 1996 Jul;22(7):548-56. Russian. PubMed PMID: 8992961.

7: Ehrsson H, Lewensohn R, Wallin I, Hellström M, Merlini G, Johansson B. Pharmacokinetics of peptichemio in myeloma patients: release of m-L-sarcolysin in vivo and in vitro. Cancer Chemother Pharmacol. 1993;31(4):265-8. PubMed PMID: 8422688.

8: Grokhovskiĭ SL, Gottikh BP, Zhuze AL. [Ligands possessing affinity to specific DNA base pair sequences. IX. Synthesis of netropsin and distamycin A analogs having sarcolysin residues or a platinum(II) atom]. Bioorg Khim. 1992 Apr;18(4):570-83. Russian. PubMed PMID: 1323966.

9: Hansson J, Lewensohn R, Ringborg U. Cytotoxicity and DNA cross-linking induced by peptide conjugated m-L-sarcolysin in human melanoma cells. Anticancer Res. 1991 Sep-Oct;11(5):1725-30. PubMed PMID: 1768043.

10: Lewensohn R, Ehrsson H, Hansson J, Ringborg U. Increased toxicity and DNA cross-linking by peptide bound m-L-sarcolysin (Peptichemio) as compared to melphalan and m-L-sarcolysin in human melanoma cell lines. Anticancer Res. 1991 Jan-Feb;11(1):321-4. PubMed PMID: 2018366.

11: Lewensohn R, Fernberg JO, Ehrsson H, Merlini G. Efficacy of peptide bound m-L-sarcolysin (peptichemio) on melphalan resistant human myeloma cells in vitro. Med Oncol Tumor Pharmacother. 1991;8(4):265-9. PubMed PMID: 1820493.

12: Lewensohn R, Hansson J, Ringborg U, Ehrsson H. Differential DNA cross-linking and cytotoxicity in PHA-stimulated human lymphocytes exposed to melphalan, m-L-sarcolysin and peptichemio. Eur J Cancer Clin Oncol. 1987 Jun;23(6):783-8. PubMed PMID: 3653195.

13: Popov DV. Antitumor activity of sarcolysin containing crosslinked copolymers in mice. Neoplasma. 1985;32(3):375-9. PubMed PMID: 4022198.

14: Ringborg U, Lambert B, Lewensohn R, Turesson I. DNA-damage in human cells treated with the closely related alkylating agents peptichemio, m-L-sarcolysin and melphalan. Eur J Cancer Clin Oncol. 1981 Sep;17(9):991-6. PubMed PMID: 7198989.

15: Morasca L, Erba E. In vitro cytotoxicity of peptichemio compared to melphalan and meta-DL-sarcolysin. Eur J Cancer. 1980 Aug;16(8):1105-9. PubMed PMID: 7439225.

16: Strigun LM, Konovalova NP. [The participation of the adrenal catecholamine system of tumor-bearing rats in sarcolysin-mediated effect]. Vopr Onkol. 1980;26(6):54-9. Russian. PubMed PMID: 7385730.

17: Balitsky KP, Veksler IG, Tsapenko VF, Kavetsky RE. The effect of the preparation "Peptichemio" on leukopoiesis and experimental tumours of animals compared with that of sarcolysin and thiophosphamide. G Ital Chemioter. 1980 Jan-Jun;27(1):1-5. PubMed PMID: 6793439.

18: Kostadinov DA, Ancheva MN, Popov DV. Effect of a sarcolysin-containing polymer on the the lymphatic tissues and immune response to sheep red blood cells. Biomedicine. 1979 Jul;31(4):85-6. PubMed PMID: 486690.

19: Presnov MA, Konovalova AL, Romanova LF, Sofina ZP, Stetsenko AI. Chemotherapy of transplantable mouse tumors with cis-dichlorodiammineplatinum(II) alone and in combination with sarcolysin. Cancer Treat Rep. 1978 May;62(5):705-12. PubMed PMID: 657156.

20: Struchkov VA, Bergol'ts VV. [Effect of sarcolysin and asalin on the incorporation of thymidine-H3 in the DNA of sarcoma 45 and tissues of tumor-bearing rats]. Biull Eksp Biol Med. 1976 May;81(5):589-91. Russian. PubMed PMID: 947383.